AstraZeneca-Ionis deal for eplontersen expands to Latin America
rafal_olechowski
Ionis Pharmaceuticals (NASDAQ:IONS) announced Friday that AstraZeneca (NASDAQ:AZN) has agreed to broaden its agreement for the companyâs investigational therapy eplontersen to include countries in Latin America.
Eplontersen, discovered by Ionis (IONS) as a self-administered subcutaneous injection, is currently under FDA review for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) with a target action date of December 22, 2023.
Following a 2021 agreement with the Carlsbad, California-based biotech, AstraZeneca (AZN) obtained exclusive rights to commercialize eplontersen outside the U.S., except in certain countries in Latin America.
Per the revised agreement, the British drugmaker has bought exclusive rights to commercialize eplontersen in Latin America in exchange for a $20M payment. The partnership to develop and commercialize eplontersen in the U.S. will continue.
The agreement allows Ionis (IONS) to receive up to $3.6B in milestone and other payments in addition to tiered royalties in the range of low double-digit to mid-20s percentages.
A Phase 3 trial is currently underway for eplontersen to evaluate its effects and safety in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

More on AstraZeneca, Ionis, etc.

AstraZeneca: Today's Hit On Lung Cancer Data - Justified Or Overblown?
AstraZeneca: What's Next? (Rating Downgrade)
Ionis: Potential Advancement Into HAE Space Makes This A Must Watch

Ionis Pharmaceuticals (IONS) Investor Presentation - Slideshow
Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?